Bioasis Technologies (BIOAF) Stock Price, News & Analysis

Company Overview

Bioasis Technologies Inc. is a biotechnology company focused on developing treatments for diseases of the central nervous system. The company’s research is centered on improving the delivery of therapeutic medicines across the blood-brain barrier, a major obstacle in the development of many neurological therapies.

Bioasis has developed its proprietary xB3 platform, which is designed to transport therapeutic molecules into the brain and other parts of the central nervous system. The platform has been investigated for use with biologic medicines and other treatments that may otherwise have limited access to the brain. The company has also pursued development and collaboration opportunities involving potential therapies for neurological and rare diseases.

Bioasis Technologies was established in Canada and has operated as an early-stage biopharmaceutical company serving the international biotechnology and pharmaceutical markets. Publicly available information about its current pipeline, operations and leadership is limited.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 10/27/2021
• Today: 11/01/2026
• Fiscal Year End: 2/28/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:BIOAF
• CIK: N/A
• Web: www.bioasis.us
• Phone: (203) 533-7082
• Fax: N/A
• Employees: 4
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.33